- MGC and Cirena are negotiating an exclusive distribution contract for long-chain RNA in Japan.
- MGC's Medium-Term Management Plan 'Grow UP 2026' focuses on innovation and strengthening its business portfolio.
- MGC partnered with Hokkaido System Science in July 2024 for nucleic acid pharmaceuticals.
- Cirena, founded in October 2024, specializes in long-chain RNA synthesis and aims to expand internationally.
Agreement Overview
Mitsubishi Gas Chemical Company, Inc. (MGC) and Cirena, Inc. have agreed to negotiate an exclusive distribution contract for long-chain RNA products in Japan. Cirena's proprietary technology enables efficient chemical synthesis of RNA extending to 300 bases, which is valuable in gene editing.
MGC's Strategic Focus
As part of its "Grow UP 2026" Medium-Term Management Plan, MGC aims to innovate and strengthen its business portfolio. The company has identified the medical and food sectors as key areas for growth, with nucleic acid pharmaceuticals being a rapidly expanding market segment.
Partnerships and Collaborations
In July 2024, MGC partnered with Hokkaido System Science Co., Ltd. to explore opportunities in the CDMO business for nucleic acid pharmaceuticals. The collaboration with Cirena aligns with MGC's strategy to enhance its capabilities in this field.
Cirena's Expansion Goals
Founded in October 2024, Cirena specializes in long-chain RNA synthesis and is focused on business development in the United States. The partnership with MGC supports Cirena's goal to expand its RNA synthesis technology internationally, with joint marketing planned outside the U.S. and Japan.
